Fig. 6From: Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapiesCost-effectiveness acceptability curves for FAc 0.2 μg/day implant vs. usual care in pseudophakic and phakic populationsBack to article page